tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lichen Nitidus D017513 1 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Mucinoses D017520 2 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Glucose Intolerance D018149 13 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fibroadenoma D018226 2 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Seminoma D018239 2 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Angiofibroma D018322 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Oral Ulcer D019226 1 associated lipids
Endotoxemia D019446 27 associated lipids
Pouchitis D019449 3 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Citrullinemia D020159 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Brain Infarction D020520 17 associated lipids
Stroke D020521 32 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Lacerations D022125 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Ileus D045823 3 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Dyslipidemias D050171 7 associated lipids
Atherosclerosis D050197 85 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Delayed Graft Function D051799 2 associated lipids
Nocturia D053158 1 associated lipids
Dysuria D053159 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Calmus Y et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. 2010 Transplantation pmid:20495510
Ouyang J et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. 2005 Transplantation pmid:15912108
Egli A et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. 2009 Transplantation pmid:19935369
Boyer O et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. 2005 Transplantation pmid:15912111
Villanueva G and Baldwin D Rosiglitazone therapy of posttransplant diabetes mellitus. 2005 Transplantation pmid:16340782
Numakura K et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. 2005 Transplantation pmid:16340785
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
de Sandes-Freitas TV et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. 2015 Transplantation pmid:25929604
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Horner BM et al. Recipient damage after musculocutaneous transplant rejection. 2008 Transplantation pmid:18946349
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Hanto DW and Chudzinski R What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? 2009 Transplantation pmid:19155968
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. 2009 Transplantation pmid:19155978
Pape E et al. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. 2015 Transplantation pmid:26308424
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Wang K et al. Transplantation of infantile bladder in rats: an alternative procedure for bladder augmentation. 2001 Transplantation pmid:11213059
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Chan L et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. 2008 Transplantation pmid:18360262
Hricik DE et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2002 Transplantation pmid:12151730
Saad ER et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. 2008 Transplantation pmid:18360267
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Todo S et al. Small intestinal transplantation in humans with or without the colon. 1994 Transplantation pmid:7512291
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Mendez R et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. 2005 Transplantation pmid:16082323
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517